Fennec Pharmaceuticals Inc. (FRX.TO)
CAD 8.12
(-6.34%)
CAD 8.12
(-6.34%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 32.76 Million USD | 37.49% |
| 2022 | 24.03 Million USD | 39.57% |
| 2021 | 17.22 Million USD | -4.61% |
| 2020 | 18.05 Million USD | 38.79% |
| 2019 | 13 Million USD | 24.98% |
| 2018 | 10.4 Million USD | 49.75% |
| 2017 | 6.95 Million USD | 142.11% |
| 2016 | 2.87 Million USD | 51.9% |
| 2015 | 1.89 Million USD | -34.31% |
| 2014 | 2.87 Million USD | 48.99% |
| 2013 | 1.93 Million USD | -46.66% |
| 2012 | 3.62 Million USD | 5.29% |
| 2011 | 3.43 Million USD | -25.33% |
| 2010 | 4.6 Million USD | 62.69% |
| 2009 | 2.83 Million USD | -79.62% |
| 2008 | 13.88 Million USD | -2.14% |
| 2007 | 14.19 Million USD | -25.56% |
| 2006 | 19.06 Million USD | 3.91% |
| 2005 | 18.34 Million USD | 0.0% |
| 2003 | 9.42 Million USD | 39.69% |
| 2002 | 6.74 Million USD | 66.91% |
| 2001 | 4.04 Million USD | 49.44% |
| 2000 | 2.7 Million USD | 68.41% |
| 1999 | 1.6 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 11.69 Million USD | 5.3% |
| 2024 Q1 | 11.1 Million USD | 1.52% |
| 2023 Q3 | 7.27 Million USD | -8.12% |
| 2023 Q1 | 6.92 Million USD | -8.7% |
| 2023 Q2 | 7.91 Million USD | 14.33% |
| 2023 Q4 | 10.93 Million USD | 50.39% |
| 2023 FY | 33.05 Million USD | 37.49% |
| 2022 Q4 | 7.58 Million USD | -3.99% |
| 2022 Q1 | 3.54 Million USD | -15.71% |
| 2022 FY | 24.03 Million USD | 39.57% |
| 2022 Q3 | 7.89 Million USD | 57.7% |
| 2022 Q2 | 5 Million USD | 41.26% |
| 2021 Q2 | 3.92 Million USD | -20.37% |
| 2021 Q3 | 4.17 Million USD | 6.45% |
| 2021 Q4 | 4.2 Million USD | 0.81% |
| 2021 FY | 17.22 Million USD | -4.61% |
| 2021 Q1 | 4.92 Million USD | 40.02% |
| 2020 Q3 | 5.85 Million USD | 20.93% |
| 2020 Q1 | 3.83 Million USD | 4.98% |
| 2020 Q4 | 3.51 Million USD | -39.99% |
| 2020 FY | 18.05 Million USD | 38.79% |
| 2020 Q2 | 4.84 Million USD | 26.34% |
| 2019 Q1 | 2.68 Million USD | -13.69% |
| 2019 Q3 | 1.86 Million USD | -61.29% |
| 2019 Q2 | 4.81 Million USD | 79.59% |
| 2019 FY | 13 Million USD | 24.98% |
| 2019 Q4 | 3.65 Million USD | 96.08% |
| 2018 Q2 | 2.66 Million USD | 48.8% |
| 2018 Q3 | 2.84 Million USD | 6.87% |
| 2018 Q4 | 3.1 Million USD | 9.02% |
| 2018 Q1 | 1.79 Million USD | -28.79% |
| 2018 FY | 10.4 Million USD | 49.75% |
| 2017 FY | 6.95 Million USD | 142.11% |
| 2017 Q2 | 1.47 Million USD | 91.83% |
| 2017 Q4 | 2.51 Million USD | 15.05% |
| 2017 Q3 | 2.18 Million USD | 47.8% |
| 2017 Q1 | 771 Thousand USD | -32.72% |
| 2016 Q4 | 1.14 Million USD | 103.19% |
| 2016 FY | 2.87 Million USD | 51.9% |
| 2016 Q1 | 454 Thousand USD | -17.6% |
| 2016 Q3 | 564 Thousand USD | -20.23% |
| 2016 Q2 | 707 Thousand USD | 55.73% |
| 2015 Q1 | 452 Thousand USD | -42.86% |
| 2015 Q3 | 338 Thousand USD | -38.43% |
| 2015 Q4 | 551 Thousand USD | 63.02% |
| 2015 Q2 | 549 Thousand USD | 21.46% |
| 2015 FY | 1.89 Million USD | -34.31% |
| 2014 Q1 | 537 Thousand USD | 29.09% |
| 2014 Q4 | 791 Thousand USD | 27.79% |
| 2014 Q2 | 930 Thousand USD | 73.18% |
| 2014 Q3 | 619 Thousand USD | -33.44% |
| 2014 FY | 2.87 Million USD | 48.99% |
| 2013 Q3 | 51 Thousand USD | -94.5% |
| 2013 Q4 | 416 Thousand USD | 715.69% |
| 2013 FY | 1.93 Million USD | -46.66% |
| 2013 Q2 | 927 Thousand USD | 72.63% |
| 2013 Q1 | 537 Thousand USD | -52.18% |
| 2012 Q1 | 616 Thousand USD | -31.71% |
| 2012 Q3 | 630 Thousand USD | -49.6% |
| 2012 Q4 | 1.12 Million USD | 78.25% |
| 2012 FY | 3.62 Million USD | 5.29% |
| 2012 Q2 | 1.25 Million USD | 102.92% |
| 2011 FY | 3.43 Million USD | -25.33% |
| 2011 Q4 | 902 Thousand USD | -4.45% |
| 2011 Q3 | 944 Thousand USD | 65.03% |
| 2011 Q2 | 572 Thousand USD | -43.98% |
| 2011 Q1 | 1.02 Million USD | 25.12% |
| 2010 Q1 | 366 Thousand USD | 186.52% |
| 2010 FY | 4.6 Million USD | 62.69% |
| 2010 Q4 | 816 Thousand USD | -11.01% |
| 2010 Q3 | 917 Thousand USD | 207366.06% |
| 2010 Q2 | 442.00 USD | -99.88% |
| 2009 FY | 2.83 Million USD | -79.62% |
| 2009 Q4 | -423 Thousand USD | -224.41% |
| 2009 Q3 | 340 Thousand USD | -64.62% |
| 2009 Q2 | 961 Thousand USD | -50.77% |
| 2009 Q1 | 1.95 Million USD | -26.06% |
| 2008 Q2 | 3.51 Million USD | -20.85% |
| 2008 Q1 | 4.43 Million USD | 39.5% |
| 2008 FY | 13.88 Million USD | -2.14% |
| 2008 Q4 | 2.64 Million USD | -19.98% |
| 2008 Q3 | 3.29 Million USD | -6.04% |
| 2007 FY | 14.19 Million USD | -25.56% |
| 2007 Q4 | 3.18 Million USD | -7.99% |
| 2007 Q1 | 4.11 Million USD | -23.46% |
| 2007 Q2 | 3.43 Million USD | -16.43% |
| 2007 Q3 | 3.45 Million USD | 0.49% |
| 2006 Q4 | 5.37 Million USD | 1.19% |
| 2006 FY | 19.06 Million USD | 3.91% |
| 2006 Q3 | 5.31 Million USD | 17.47% |
| 2006 Q2 | 4.52 Million USD | 17.45% |
| 2006 Q1 | 3.85 Million USD | -25.78% |
| 2005 Q3 | 4.8 Million USD | -2.82% |
| 2005 Q2 | 4.94 Million USD | 44.58% |
| 2005 Q1 | 3.41 Million USD | 0.0% |
| 2005 Q4 | 5.18 Million USD | 8.08% |
| 2005 FY | 18.34 Million USD | 0.0% |
| 2004 Q1 | 2.7 Million USD | 25.35% |
| 2004 Q3 | 3.15 Million USD | 8.71% |
| 2004 Q2 | 2.9 Million USD | 7.27% |
| 2003 Q2 | 2.34 Million USD | 23.52% |
| 2003 FY | 9.42 Million USD | 39.69% |
| 2003 Q4 | 2.16 Million USD | 31.92% |
| 2003 Q3 | 1.63 Million USD | -30.21% |
| 2003 Q1 | 1.89 Million USD | 61.39% |
| 2002 Q3 | 1.14 Million USD | -23.24% |
| 2002 Q2 | 1.49 Million USD | 64.08% |
| 2002 Q1 | 909.61 Thousand USD | 30.83% |
| 2002 FY | 6.74 Million USD | 66.91% |
| 2002 Q4 | 1.17 Million USD | 2.75% |
| 2001 Q2 | -2.64 Million USD | 0.0% |
| 2001 FY | 4.04 Million USD | 49.44% |
| 2001 Q4 | 695.25 Thousand USD | -27.07% |
| 2001 Q3 | 953.32 Thousand USD | 135.99% |
| 2001 Q1 | - USD | -100.0% |
| 2000 FY | 2.7 Million USD | 68.41% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q4 | 558.82 Thousand USD | 0.0% |
| 1999 FY | 1.6 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Appili Therapeutics Inc. | 8.83 Million CAD | -270.762% |
| Eupraxia Pharmaceuticals Inc. | 37.92 Million CAD | 13.606% |
| Helix BioPharma Corp. | 9.35 Million CAD | -250.155% |
| Microbix Biosystems Inc. | 10.21 Million CAD | -220.657% |
| Medicenna Therapeutics Corp. | 19.66 Million CAD | -66.628% |
| Satellos Bioscience Inc. | 6.64 Million CAD | -392.988% |
| Oncolytics Biotech Inc. | 33.79 Million CAD | 3.039% |
| Sernova Corp. | 41.13 Million CAD | 20.342% |